摘要
目的分析内分泌治疗在与89SrCl2联合治疗前列腺癌骨转移过程中所起到的作用.方法 127例确诊前列腺癌骨转移伴有疼痛且接受过睾丸切除术治疗的患者被分为3组:其中A组的70例患者接受了内分泌联合89SrCl2治疗;B组的35例只接受了89锶治疗;C组的22例患者只接受了内分泌治疗.比较治疗前和治疗3个月后的VAS评分、骨转移灶的变化情况、PSA变化情况.结果各组之间在治疗前的VAS评分3组之间无统计学差异(P>0.05),治疗后A、B组疼痛较治疗前减轻明显(P<0.05),C组疼痛缓解不明显(P>0.05);A组与B组间的疼痛缓解程度无差异(P>0.05),而A、B组与C组之间有差异(P<0.05).骨扫描显示骨转移灶好转率A组效果较B、C组好(P<0.05),B组与C组无差异(P>0.05).PSA减低幅度,A组与C组减低不明显(P〉0.05),B组减低程度要大于A、C组(P<0.05).结论单独利用89SrCl2或内分泌治疗前列腺癌骨转移不能同时有效的控制疼痛和骨转移灶的发展.同时配合两种治疗可提高疼痛缓解效果并能更好的治疗骨转移灶.
Objective To analyse the therapeutic effect of strontium-89combined with endocrine therapy of bone metastases in treatment of patients with prostate cancer. Methods 127 prostate cancer patients with bone metastasis who got castrate operation only and felt pain due to bone metastasis from Jan 2009 to Dec 2010 were divided into 3 groups. 70 patients of them was in A group and got strontium-89-chloride and medical castration, 35 patients of them was in B group and got strontium-89-chloride therapy only and 22 patients of them was in C group and got medical castration only. The VAS score, the ECT bone scanning and the PSA before and 3 months after treatment were compared among three group. Results Before therapy, the VAS scores of A, B, C groups had no statistically significant difference (P 〉 0.05) . After therapy, the pain in patients in A and B groups was significantly alleviated (P 〈 0.05) but in C group was not significantly alleviated (P 〉 0.05) . There was no statistically significant difference in VAS scores between A and B groups after therapy (P 〉 0.05) , while there was a statistically significant difference between A and C group or B and C group (P 〈 0.05) . ECT bone scanning showed the improvement rate of bone metastasis was better in A group than B and C group (P 〈 0.05) , and there was no no statistically significant difference between B and C group (P 〉 0.05) . The reducing rate of PSA was not statistically significant in A and C group (P〉 0.05), while was higher in B group than in A and C group (P 〈 0.05). Conclusion Single use of Strontium-89-chloride or medical castration couldn't improve the bone metastasis and the pain of prostate cancer patients with bone metastasis, while combination of the two treatment methods could improve the effect of reducing the pain and control the bone metastasis at the same time.
出处
《昆明医科大学学报》
CAS
2013年第4期122-124,共3页
Journal of Kunming Medical University
关键词
89SrCl2
药物去势
前列腺癌
骨转移
Strontium-89-chloride
Medical castration
Prostate cancer
Bone metastasis